WFH/LinkedIn
Feb 28, 2026, 14:48
WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“WFH Statement: the WFH acknowledges BioMarin’s decision to discontinue ROCTAVIAN and the importance of this development for the hemophilia community.
We urge BioMarin and other gene therapy developers to continue rigorous long-term safety monitoring of all discontinued products, and to preserve and share relevant clinical data that can inform ongoing scientific understanding and support patient safety.
For the full WFH position and our emphasis on preserving data in the WFH Gene Therapy Registry, please read our complete statement here.”
Other articles about World Federation of Hemophilia on Hemostasis Today.
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice
-
Sep 1, 2026, 18:06Wei Du: New Therapeutic Potential for PARP Inhibitors in MLL-Rearranged Leukemia
-
Sep 1, 2026, 18:03Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound
-
Sep 1, 2026, 18:00Baptiste Thibault: My First Publication as First Author on Ionized Calcium Monitoring Before Citrate-CRRT
-
Sep 1, 2026, 17:51Nadezhda Vasilyeva: Shifting the Boundaries of Acute Ischemic Stroke Management
-
Sep 1, 2026, 17:49Malik Ghannam: Recent Venous Thrombosis Risk Factors May Help Explain Cryptogenic Stroke in Young Adults
-
Sep 1, 2026, 17:42Rishabh Jain: Renal Artery FMD Is Managed With Balloon Angioplasty Alone
-
Sep 1, 2026, 17:42Caitlin R: The Brain’s Need to Find Patterns